Loading...
NPI 1801258736 · Rosedale, MD · Methadone Clinic
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Riverside Treatment Services LLC is a methadone clinic provider located in Rosedale, Maryland. This profile covers 3 Medicare and 12 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Riverside Treatment Services LLC |
| Address | 8359 Pulaski Highway |
| City | Rosedale |
| State | MD |
| ZIP | 21237 |
| Taxonomy | Methadone Clinic |
| NPI Enumerated | March 21, 2016 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $56.3M |
| Medicare | $1M |
Payer mix is heavily skewed toward Medicaid: lifetime Medicaid revenue is $56.3M versus total Medicare revenue of $1M, indicating the provider is effectively a Medicaid-focused operation rather than a Medicare-driven practice. This scale difference suggests most clinical activity and cash flow depend on state Medicaid reimbursement and patient populations.
Medicare revenue is highly concentrated in opioid treatment program bundles: the provider’s top three Medicare codes account for 100.0% of Medicare revenue, led by G2067 ($840.4K, 81.5%), followed by G2078 ($124.6K, 12.1%) and G2068 ($66.3K, 6.4%). These codes reflect weekly medication-assisted treatment bundles, take-home methadone supplies, and buprenorphine bundles, confirming that Medicare billing is concentrated in OTP-style weekly services rather than disparate office-based E/M or ancillary services.
On Medicare competitive standing, the provider shows a mixed picture: G2078 ranks #3 of 493 providers nationally (100th percentile; notably above typical national volume for this code), while G2067 ranks #26 of 830 (97th percentile; typical, unremarkable volume for this code) and G2068 ranks #8 of 13 (42th percentile; typical, unremarkable). In practical terms, the clinic is a nationally notable biller for take-home methadone supply but otherwise occupies a more ordinary national position for the primary weekly OTP bundle and a limited role for buprenorphine under Medicare.
Medicaid revenue is highly concentrated in a few core service lines: the top three Medicaid codes account for 82.1% of Medicaid revenue, with H0020 at $28.4M (50.6%), H0004 at $9.4M (16.8%), and J0574 at $8.3M (14.7%). This concentration shows the organization’s Medicaid business is driven primarily by methadone administration, behavioral health counseling/therapy, and substantial buprenorphine/naloxone dispensing, indicating an integrated MAT and counseling service model.
The provider is a dominant statewide player on key Medicaid codes: H0020 ranks #2 of 108 in-state (99th percentile; extreme outlier, far above typical state volume for this code), H0004 ranks #2 of 382 (100th percentile; extreme outlier), and J0574 ranks #1 of 36 (100th percentile; extreme outlier). These rank/percentile signals identify the clinic as an extreme outlier in Maryland for methadone administration, counseling, and buprenorphine dispensing, implying strong market share and operational scale within the state Medicaid system.
Operational throughput is substantial on Medicaid billing lines, consistent with a high-volume opioid treatment program: reported claim counts include 373.5K claims for H0020, 412.6K claims for J0574, and 108.3K claims for H0004, reflecting continuous dosing/dispensing cycles and frequent counseling encounters. By contrast, Medicare claim volumes are much smaller in absolute terms (e.g., 3.9K G2067 claims), reinforcing that day-to-day service delivery and patient volume are concentrated in the Medicaid population.
Service-line mix shows an integrated MAT model that combines daily/weekly medication dispensing with counseling and assessment: codes include methadone administration (H0020/G2067), take-home methadone supply (G2078), multiple buprenorphine strengths (J0574, J0572, J0573), counseling (H0004/H0047), and assessment (H0001). This combination of high-volume dispensing plus extensive behavioral health counseling is typical of a methadone clinic operating both medication dispensing and psychosocial support workflows.
The provider has an established operational history with NPI enumeration on 2016-03-21 (~10 years ago), supporting the interpretation that the observed high Medicaid volumes and dominant in-state ranks reflect sustained activity rather than a short-term billing spike. Given the consistent, large-scale Medicaid billing and statewide outlier status on multiple Medicaid codes, the organization appears to be a long-standing, high-capacity opioid treatment provider in Maryland.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
3 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed… | 3,930 | $210 | $840.4K |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | 3,560 | $40 | $124.6K |
| G2068 | Medication assisted treatment, buprenorphine (oral); weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing if… | 260 | $260 | $66.3K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 3 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 373,510 | $80 | $28.4M |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 108,280 | $90 | $9.4M |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 412,630 | $20 | $8.3M |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | 68,760 | $70 | $4.6M |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | 176,300 | $10 | $2.3M |
| H0001 | Alcohol and/or drug assessment | 10,450 | $180 | $1.8M |
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 3,480 | $240 | $848.1K |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | 9,900 | $20 | $217.8K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,870 | $80 | $140.2K |
| 99211 | An established patient presents for an office or other outpatient visit that may not require the presence of a physician or other qualified healthcare professional. | 3,130 | $20 | $68.9K |
Showing 1–10 of 12
How this provider's Medicaid billing volume and revenue compare to other Maryland providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Maryland median
12 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 2 | 110 | 51,720 | $70 | $4.8M |
| J0574 | Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine | 1 | 40 | 9,260 | $20 | $756.2K |
| H0047 | Alcohol and/or other drug abuse services, not otherwise specified | 1 | 50 | 2,370 | $70 | $484.7K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | 2 | 380 | 1,450 | $60 | $459K |
| J0572 | Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine | 1 | 30 | 11,420 | $10 | $307.4K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,037 | 3,280 | 610 | $80 | $296.1K |
| H0016 | Alcohol and/or drug services; medical/somatic (medical intervention in ambulatory setting) | 3 | 80 | 240 | $240 | $141.1K |
| J0573 | Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine | 6 | 20 | 3,590 | $20 | $130.9K |
| H0001 | Alcohol and/or drug assessment | 1 | 440 | 190 | $170 | $115.9K |
| 99211 | An established patient presents for an office or other outpatient visit that may not require the presence of a physician or other qualified healthcare professional. | 31 | 400 | 150 | $20 | $43.7K |
Showing 1–10 of 12
Other providers in the same ZIP code as Riverside Treatment Services LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.